Amphastar Pharmaceuticals Inc. Founded in 1996, the company has become a prominent player in the global market, focusing on the development, manufacture, and marketing of generic and proprietary injectable and inhalation products. Amphastar is headquartered in Rancho Cucamonga, California.

The company's corporate campus spans over 500,000 square feet and houses its research and development laboratories, manufacturing facilities, quality control laboratories, and administrative offices. The company's main products and services revolve around generic and proprietary injectable and inhalation pharmaceuticals. They offer a diverse portfolio of essential medicines that include specialized drugs for emergency and critical care, such as anticoagulants, anesthesia agents, and neuromuscular blocking agents.

Furthermore, Amphastar provides products for allergy and respiratory conditions, as well as for pain management and cancer treatment. On a global scale, Amphastar has strategically expanded its reach through partnerships, subsidiaries, and joint ventures. Notably, the company has an agreement with Armstrong Pharmaceuticals Inc., a subsidiary that focuses on developing orphan drugs.

Amphastar has also entered into contracts to supply products to multinational and international pharmaceutical companies. Amphastar maintains a strong market position with its products distributed in the United States and various international markets. With a commitment to quality and regulatory compliance, the company has successfully competed with other pharmaceutical giants in the industry.

Its global sales have steadily grown, establishing Amphastar as a trusted and reliable supplier of critical therapeutics. In terms of major events, Amphastar has achieved several milestones throughout its existence. In 2003, the company received FDA approval for Amphadase®, a hyaluronidase injection.

This breakthrough product enhances the absorption and dispersion of other injected drugs. Another significant accomplishment was the development of Primatene Mist®, an over-the-counter epinephrine inhaler for the temporary relief of mild symptoms of intermittent asthma. As of the latest available information, Amphastar continues to thrive in the pharmaceutical industry.

The company remains dedicated to research and development, seeking to expand its product portfolio and provide innovative solutions to healthcare providers and patients worldwide. With its commitment to excellence, Amphastar aims to further strengthen its market position and contribute to improving global healthcare outcomes